Susan Hohenleitner serves as Chief Financial Officer at Ardelyx, Inc., a biopharmaceutical company dedicated to developing innovative therapies for gastrointestinal and cardiorenal diseases. Appointed in September 2021, she oversees all financial operations, including strategic planning, capital allocation, investor relations, and treasury management. With more than 25 years of experience in the biotechnology and pharmaceutical sectors, Susan has established herself as a seasoned finance leader adept at navigating complex capital markets, financings, and corporate transactions. Prior to Ardelyx, Susan was CFO at Relypsa, Inc., from 2013 to 2016, where she spearheaded the company's initial public offering on NASDAQ, raised significant capital, and guided its $1.1 billion acquisition by Vifor Fresenius Medical Care Renal Pharma (now part of Vifor Pharma). Her earlier career includes senior finance roles at Nektar Therapeutics, Genentech, and Applied Biosystems, where she managed global financial reporting, budgeting, and M&A activities. Throughout her tenure, she has successfully raised over $1 billion in equity and debt financings, earning recognition for her strategic acumen in high-growth biotech environments. At Ardelyx, Susan has played a pivotal role in advancing the company's financial strategy amid key milestones, including the FDA approvals and commercial launches of IBSRELA® for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH® for hyperphosphatemia in chronic kidney disease patients on dialysis. Her leadership has strengthened Ardelyx's balance sheet, supported revenue growth, and positioned the company for sustained innovation and shareholder value creation in the competitive biopharma landscape.